Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 207 for “"DLBCL"”.

  1. Κυτταρική θεραπεία με CAR T σε ασθενείς με λέμφωμα DLBCL (Μεγαλοκυτταρικό B-λέμφωμα)

    … μεγάλα Β-κύτταρα (Diffuse Large B-cell Lymphoma, DLBCL) περιλαμβάνει μία ετερογενή ομάδα μορφολογικά, γενετικά, και κλινικά διακριτών ασθενειών. Εμφανίζεται κυρίως σε άτομα μεγαλύτερα των 60 ετών, παρόλα αυτά μπορεί να εμφανιστεί και σε παιδιά και εφήβους. Η αιτιολογία της νόσησης από DLBCL …

    athens Repository record for Κυτταρική θεραπεία με CAR T σε ασθενείς με λέμφωμα DLBCL (Μεγαλοκυτταρικό B-λέμφωμα) (opens in a new tab)

  2. Funktionelle Validierung von Onkogenen bei molekularen Subtypen von diffusen großzelligen B-Zell Lymphomen (DLBCL)

    Das diffuse großzellige B-Zell Lymphom (DLBCL) stellt mit einem Anteil von ca. 30-40% den häufigsten Lymphom-Subtyp bei Erwachsenen dar. Es ist eine heterogene diagnostische Kategorie, die anhand von Genexpressionsanalysen in zwei vorherrschende molekulare Subtypen unterteilt werden kann: Den …

    fu-berlin Repository record for Funktionelle Validierung von Onkogenen bei molekularen Subtypen von diffusen großzelligen B-Zell Lymphomen (DLBCL) (opens in a new tab)

  3. Inhibition of Fatty Acid Amide Hydrolase Increases Rates of Apoptosis in Cell Line Models of DLBCL and Breast Cancer

    … cancers with high heterogeneity such as DLBCL and breast cancer remain difficult to treat, with many patients having few treatment options. The endocannabinoid system has been identified as a potential wellspring of therapeutic agents that can potentially increase cell death and prevent …

    houston Repository record for Inhibition of Fatty Acid Amide Hydrolase Increases Rates of Apoptosis in Cell Line Models of DLBCL and Breast Cancer (opens in a new tab)

  4. Unraveling the Underlying Mechanism of Bcl-2 Mutations Regulated Apoptotic Blocks in Diffuse Large B-Cell Lymphoma (Dlbcl) Patients

    … data obtained from a large series of DLBCLs have identified frequent mutations in the translocated BCL2 gene. However, the heterogeneity of the mutation profile complicates the prediction of the functional effects of the DLBCL-specific mutations. The aim of the research is to present …

    houston Repository record for Unraveling the Underlying Mechanism of Bcl-2 Mutations Regulated Apoptotic Blocks in Diffuse Large B-Cell Lymphoma (Dlbcl) Patients (opens in a new tab)

  5. Characterizing Therapy Induced Polyploidy (TIP) Populations as a Resistance Mechanism in DH/DE-DLBCL and Identifying Synthetic Lethal Targeted Therapies

    … cancer in USA. Diffuse large B-cell lymphoma (DLBCL) and Peripheral T-cell lymphoma (PTCL) are the most common types of aggressive B-cell and T-cell non-Hodgkin lymphomas (NHL) respectively. Double-Hit or Double-Expresser DH/DE-DLBCL are high grade B-cell lymphomas characterized by …

    arizona-thes Repository record for Characterizing Therapy Induced Polyploidy (TIP) Populations as a Resistance Mechanism in DH/DE-DLBCL and Identifying Synthetic Lethal Targeted Therapies (opens in a new tab)

  6. Elucidation of the Mechanisms of Resistance and Sensitivity to Histone Deacetylase Inhibitor, PXD101, in Diffuse Large B-Cell Lymphoma (DLBCL)

    … of cases, Diffuse Large B-cell Lymphoma (DLBCL), the most prevalent Non-Hodgkin Lymphoma (NHL) throughout the world, is still fatal for 30-40% patients. This patient population could benefit from the addition of new drugs to the current DLBCL chemotherapy regimen. Histone deacetylase …

    arizona-thes Repository record for Elucidation of the Mechanisms of Resistance and Sensitivity to Histone Deacetylase Inhibitor, PXD101, in Diffuse Large B-Cell Lymphoma (DLBCL) (opens in a new tab)

  7. Genetische Charakterisierung diffuser großzelliger B-Zell Lymphome vom Keimzentrumstyp, vom aktivierten B-Zelltyp und von primär mediastinalen diffusen großzelligen B-Zell Lymphomen

    Diffuse großzellige B-Zell Lymphome (DLBCL) gehören zu den häufigsten lymphatischen Tumoren. Die histologische Klassifikation dieser großen Gruppe von Tumoren ist dabei noch immer durch die mangelnde Reproduzierbarkeit in der Diagnostik geprägt. Außerdem verhalten sich DLBCL klinisch ausgesprochen …

    wurz-thes Repository record for Genetische Charakterisierung diffuser großzelliger B-Zell Lymphome vom Keimzentrumstyp, vom aktivierten B-Zelltyp und von primär mediastinalen diffusen großzelligen B-Zell Lymphomen (opens in a new tab)

  8. Διερεύνηση των μοριακών μηχανισμών του Μεταγωγέα Σήματος και Ενεργοποιητή της Μεταγραφής 3 (STAT3) στο Διάχυτο Λέμφωμα από Μεγάλα Β Κύτταρα

    … μεγάλα Β-κύτταρα (Diffuse Large B Cell Lymphoma, DLBCL) αποτελεί τον πλέον διαδεδομένο τύπο λεμφώματος μη Hodgkin, και παρουσιάζει μεγάλη ετερογένεια στη νόσο ως προς τις θέσεις εμφάνισης του όγκου, τα μοριακά χαρακτηριστικά και την κλινική συμπτωματολογία. Το DLBCL μπορεί να διαχωριστεί σε δύο …

    athens Repository record for Διερεύνηση των μοριακών μηχανισμών του Μεταγωγέα Σήματος και Ενεργοποιητή της Μεταγραφής 3 (STAT3) στο Διάχυτο Λέμφωμα από Μεγάλα Β Κύτταρα (opens in a new tab)

  9. The Impact of Diffuse Large B-Cell Lymphoma on Primary Care and Costs of Chronic Conditions in Elderly Medicare Beneficiaries

    Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of Non-Hodgkin's lymphoma with a median age of diagnosis of 67 years. The intensive treatment of DLBCL can negatively influence elderly patients' preventive and chronic care, which can increase the costs of different chronic conditions. …

    wvu Repository record for The Impact of Diffuse Large B-Cell Lymphoma on Primary Care and Costs of Chronic Conditions in Elderly Medicare Beneficiaries (opens in a new tab)

  10. Die Rolle des Tumorsuppressors PTEN bei der molekularen Pathogenese diffuser großzelliger B-Zell-Lymphome

    Diffuse großzellige B-Zell-Lymphome (DLBCL) repräsentieren den häufigsten Subtyp maligner Lymphome. Sie stellen bezüglich ihrer Morphologie, Biologie, und ihres klinischen Verlaufes eine sehr heterogene Gruppe von Erkrankungen dar. Durch genomweite Genexpressionsstudien konnten zwei vorherrschende …

    fu-berlin Repository record for Die Rolle des Tumorsuppressors PTEN bei der molekularen Pathogenese diffuser großzelliger B-Zell-Lymphome (opens in a new tab)

  11. The hematopoietic oncoprotein FOXP1 promotes cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling

    Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non- Hodgkin lymphoma. With current treatment regimens, a substantial part of DLBCL patients can be cured. However, up to 40% will not achieve durable remissions and eventually will succumb to recurrent disease. Using gene expression …

    zurich Restricted access

  12. Biomarker identification in HIV and non-HIV related lymphomas

    DLBCL is the most common lymphoma subtype occurring in older populations as well as in younger HIV infected patients. The current treatment options for DLBCL are effective for most patients yet the relapse rate is high. While many biomarkers for DLBCL exist, they are not in clinical use due to low …

    cape-town Repository record for Biomarker identification in HIV and non-HIV related lymphomas (opens in a new tab)

  13. Die Rolle von NFATc1 bei der molekularen Pathogenese von diffusen großzelligen B-Zell-Lymphomen

    Diffuse großzellige B-Zell-Lymphome (DLBCL) sind aggressive Neoplasien reifer B-Zellen und repräsentieren die häufigsten neu diagnostizierten Lymphome. Genexpressionsanalysen gelang die Differenzierung der heterogenen DLBCL in mindestens zwei vorherrschende molekulare Subtypen, mit einem …

    fu-berlin Repository record for Die Rolle von NFATc1 bei der molekularen Pathogenese von diffusen großzelligen B-Zell-Lymphomen (opens in a new tab)

  14. Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma

    Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Identification of prognostic and predictive markers is important to design individualised and effective treatment strategies. This thesis describes different approaches to search for molecular prognostic markers and …

    lund Repository record for Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma (opens in a new tab) Download PDF for Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma (opens in a new tab)

  15. TARGETING DNA DAMAGE RESPONSE KINASES TO IMPROVE CHEMOTHERAPY EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA

    Diffuse large B cell lymphoma (DLBCL) is the most common form of Non-Hodgkin’s Lymphoma, and about half of the patients relapse or are refractory to first line treatment, R-CHOP—an immunochemotherapy consisting of Rituximab and chemotherapy agents. Targeting the DNA Damage Response (DDR) pathway …

    nus Repository record for TARGETING DNA DAMAGE RESPONSE KINASES TO IMPROVE CHEMOTHERAPY EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA (opens in a new tab) Download file for TARGETING DNA DAMAGE RESPONSE KINASES TO IMPROVE CHEMOTHERAPY EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA (opens in a new tab)

  16. Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation

    Diffuse Large B cell Lymphoma (DLBCL) is an aggressive disease that displays striking heterogeneity at both the molecular and clinical levels; and as a result, up to 40% of patients relapse or are refractory to standard first-line therapy. DLBCL is the most common subtype of lymphoma affecting …

    cape-town Repository record for Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation (opens in a new tab)

  17. The role of sphingosine-1-phosphate on macrophage recruitment and function in diffuse large B-cell lymphoma

    Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Currently, approximately 40% of DLBCL patients treated with standard of care therapies, which include a combination of immunotherapy (Rituximab; R) and chemotherapy (CHOP), will have disease that is refractory or will …

    birmingham Download PDF for The role of sphingosine-1-phosphate on macrophage recruitment and function in diffuse large B-cell lymphoma (opens in a new tab)

Page 1 of 11